Cargando…

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

BACKGROUND: AST1306 is an orally active irreversible small molecule inhibitor of EGFR (erbB1), HER2 (erbB2) and HER4 (erbB4) signaling. This is a phase I, open-label, dose-escalation study to evaluate the safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor effects of oral AST1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jian, Cao, Junning, Li, Jin, Zhang, Yifan, Chen, Zhiyu, Peng, Wei, Sun, Si, Zhao, Naiqing, Wang, Jiachen, Zhong, Dafang, Zhang, Xiaofang, Zhang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007625/ https://www.ncbi.nlm.nih.gov/pubmed/24612546 http://dx.doi.org/10.1186/1756-8722-7-22

Ejemplares similares

AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo
por: Xie, Hua, et al.
Publicado: (2011)

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
por: Kim, Tae Min, et al.
Publicado: (2018)

The first true millipede—1306 legs long
por: Marek, Paul E., et al.
Publicado: (2021)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
por: Wu, Yifen, et al.
Publicado: (2015)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Role of MMP-2 (-1306 C/T) Polymorphism in Pituitary Adenoma
por: Glebauskiene, Brigita, et al.
Publicado: (2016)

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
por: Hu, Chen, et al.
Publicado: (2017)

Angular analysis of $ {B}^0\to {D}^{\ast -}{D}_s^{\ast +} $ with $ {D}_s^{\ast +}\to {D}_s^{+}\gamma $ decays
por: Aaij, Roel, et al.
Publicado: (2021)

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib
por: Huang, Qiang, et al.
Publicado: (2015)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors
por: Zhang, Nana, et al.
Publicado: (2022)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

UP1306, a Botanical Composition with Analgesic and Anti-inflammatory Effect
por: Yimam, Mesfin, et al.
Publicado: (2016)

Test of HQET with B^\ast, B^\ast \ast and lifetime measurements of B_s mesons and beauty baryons at DELPHI
por: Siccama, I
Publicado: (1995)

Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer
por: Zhang, Tongtong, et al.
Publicado: (2016)

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
por: Eskens, F A L M, et al.
Publicado: (2008)

Biochemical and transcriptomic analyses of drought stress responses of LY1306 tobacco strain
por: Yang, Huijuan, et al.
Publicado: (2017)

miR-1306 induces cell apoptosis by targeting BMPR1B gene in the ovine granulosa cells
por: Abdurahman, Anwar, et al.
Publicado: (2022)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: a meta-analysis based on 3906 subjects
por: Zhang, Kaiping, et al.
Publicado: (2017)

Structure and dynamics of the EGFR/HER2 heterodimer
por: Bai, Xue, et al.
Publicado: (2023)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer
por: Agarwal, Neeraj, et al.
Publicado: (2022)

Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
por: Park, Soon Young, et al.
Publicado: (2023)

1306. Antimicrobial Resistance Knowledge, Attitudes, and Perceptions Among Medical Students in Southern India
por: Menden, Olivia, et al.
Publicado: (2018)

P1306: CLINICAL AND GENOMIC ANALYSIS OF HIGH-GRADE TRANSFORMATION OF MARGINAL ZONE LYMPHOMA
por: Yannakou, C., et al.
Publicado: (2022)

First Observation of the B ^\ast Dalitz Decay B ^\ast -> B\ e ^+ e ^-
por: DELPHI Collaboration
Publicado: (2018)

Antibiotic Susceptibility Testing (AST) Practices in India: Need for a National AST Forum
por: Borde, Kalyani, et al.
Publicado: (2022)

Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials
por: Zhang, Yiliang, et al.
Publicado: (2013)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

AST Six Pack Premium
por: Basson, Craig Todd
Publicado: (1987)

$R(D^\ast)$ status
por: Wormser, Guy Henri Maurice
Publicado: (2017)

The Regulatory Mechanism of Transthyretin Irreversible Aggregation through Liquid-to-Solid Phase Transition
por: Duan, Guangfei, et al.
Publicado: (2023)

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
por: Bahleda, Rastislav, et al.
Publicado: (2018)

TINNET COST Action BM1306: an international standard for outcome measurements in clinical trials of tinnitus
por: Hall, Deborah, et al.
Publicado: (2015)

P1306: IMPACT OF HLA DISPARITY ON THE RISK OF OVERALL MORTALITY IN PATIENTS WITH EXTENSIVE CHRONIC GVHD
por: Fuji, Shigeo, et al.
Publicado: (2023)

The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma
por: Zhang, Li-xiang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k9lc62c57l0lpi2fe7q1fn7fqo